5-溴-2,3-二甲氧基吡啶 | 52605-98-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-溴-2,3-二甲氧基吡啶
• 中文别名: 2,3-二甲氧基-5-溴吡啶；2,3-二甲氧基-溴吡啶
• 英文名称: 5-bromo-2,3-dimethoxypyridine
• 英文别名: 2,3-dimethoxy-5-bromopyridine；5-bromo-2,3-dimethoxy-pyridine；5-Brom-2,3-dimethoxy-pyridin
• CAS: 52605-98-8
• 化学式: C₇H₈BrNO₂
• 分子量: 218.05
• InChiKey: VSXDRIVAPWWONE-UHFFFAOYSA-N

物化性质

• 沸点：
  222.7±35.0 °C(Predicted)
• 密度：
  1.484±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338
• 储存条件：
  存储于惰性气体保护下并在室温条件下

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-2,3-dimethoxypyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2,3-dimethoxypyridine
CAS number: 52605-98-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BrNO2
Molecular weight: 218.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2,3-二甲氧基吡啶 在 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 吡啶 、 盐酸 、 水 、 sulfur 、 N,N-二异丙基乙胺 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 氯仿 、 甲苯 为溶剂， 反应 7.0h， 生成 2-[[5-(5,6-dimethoxypyridin-3-yl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]carbamoylamino]-N-propan-2-ylbenzamide
  参考文献：
  名称：

  EP2426135

  摘要：

  公开号：
• 作为产物：
  描述：

  3-溴-5-甲氧基吡啶-1-氧化物 在 三氯氧磷 作用下， 以 氯仿 为溶剂， 反应 14.0h， 生成 5-溴-2,3-二甲氧基吡啶
  参考文献：
  名称：

  EP2426135

  摘要：

  公开号：

文献信息

• D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Tsai Guochuan Emil

  公开号：US20190112289A1

  公开（公告）日：2019-04-18

  The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L 1 and L 2 , independently, is a moiety selected from O, CH 2 , C═O, C 2-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, —((CH 2 ) n —W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L 2 is absent, Z is aryl or heteroaryl fused with B C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中：A、B、C、D 和 E 中的每一个独立地是 C、N、N—H、O、S 或不存在 是单键或双键；X、Y 和 Z 中的每一个独立地是芳基、杂环芳基、芳基烷基、H 或不存在；L 1 和 L 2 中的每一个独立地是从 O、CH 2 、C═O、C 2-10 烷基、C 2-10 烯基、C 2-10 炔基、—((CH 2 ) n —W)— 中选择的基团，其中 n=0、1、2、3、4 或 5，W 是 O 或 S，或不存在；当 L 2 不存在时，Z 是与 B 相融合的芳基或杂环芳基。本发明还提供了一种用于抑制、治疗和/或减少神经精神障碍风险的方法，包括向需要的受试者施用包含式（I）化合物的组合物。
• 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用
  申请人：广东克冠达医药科技有限公司

  公开号：CN110498784B

  公开（公告）日：2022-06-14

  本发明公开了一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用。所述川陈皮素衍生物的结构如式(Ⅰ)所示；其中，R1、R2、R3和R4分别选自氢、卤素、羟基、氨基、C1‑6取代或非取代烷氧基、C1‑6取代或非取代酯基、C1‑6取代或非取代烷胺基、C1‑6取代或非取代酰胺基；R5选自C3‑9取代或非取代芳香环、C3‑9取代或非取代芳香杂环；X选自O或NR6。本发明所述川陈皮素衍生物或其药学上可接受的盐结构新颖，且化合物对于P‑gp均表现出优异的抑制作用，可制备成为P‑gp抑制剂进行使用，治疗和/或预防由P‑gp引发的相关疾病，特别是肿瘤耐药相关的疾病；或与其他药物混配使用，作为耐药性逆转剂进行应用，逆转倍数高，可显著性地提高药物的药效。
• Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units
  作者：Peter J. Choi、Hamish S. Sutherland、Amy S.T. Tong、Adrian Blaser、Scott G. Franzblau、Christopher B. Cooper、Manisha U. Lotlikar、Anna M. Upton、Jerome Guillemont、Magali Motte、Laurence Queguiner、Koen Andries、Walter Van den Broeck、William A. Denny、Brian D. Palmer

  DOI：10.1016/j.bmcl.2017.10.042

  日期：2017.12

  bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive correlation between lipophilicity and anti-TB activity, the 4-pyridyl derivatives appeared to have an additional contribution to antibacterial potency. The majority of the compounds were (desirably)

  合成并评估了苯达喹啉的类似物，其中苯B单元被亲脂性差异很大的单环杂环（噻吩，呋喃，吡啶）取代。虽然亲脂性和抗结核活性之间存在广泛的正相关关系，但4-吡啶基衍生物似乎对抗菌效力具有额外的贡献。与贝达喹啉相比，大多数化合物的极性更大（清除率更高），清除率更高，并显示出可接受的口服生物利用度，但其hERG耐受性的改善有限（且无法预测）。
• [EN] TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDRO-PYRIDO-PYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2012004299A1

  公开（公告）日：2012-01-12

  The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

  这项发明涉及公式（I）中Y、R1、R2和m所定义的替代四氢吡啶嘧啶衍生物。这些化合物适用于治疗由PI3K酶活性介导的疾病或疾病。
• Use of Inhibitors of the Activity or Function of PI3K
  申请人：NOVARTIS AG

  公开号：US20150342951A1

  公开（公告）日：2015-12-03

  The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

  该发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同工酶δ具有抑制作用，用于治疗患有疟疾、利什曼病、锥虫病、弓形虫病和/或神经囊虫病等疾病或紊乱的受试者的免疫病理学，通过对感染受试者的TLR9的功能抑制。